Center for Vaccine Research, University of Pittsburghgrid.21925.3d School of Medicine, Pittsburgh, Pennsylvania, USA.
Department of Microbiology and Molecular Genetics, University of Pittsburghgrid.21925.3d School of Medicine, Pittsburgh, Pennsylvania, USA.
mSphere. 2021 Oct 27;6(5):e0053721. doi: 10.1128/mSphere.00537-21. Epub 2021 Sep 22.
Defective interfering (DI) genomes restrict viral replication and induce type I interferon. Since DI genomes have been proposed as vaccine adjuvants or therapeutic antiviral agents, it is important to understand their generation, delineate their mechanism of action, develop robust production capacities, assess their safety and longevity, and determine their long-term effects. To address this, we generated a recombinant canine distemper virus (rCDV) from an entirely synthetic molecular clone designed using the genomic sequence from a clinical isolate obtained from a free-ranging raccoon with distemper. rCDV was serially passaged to identify DI genomes that naturally arise during rCDV replication. Defective genomes were identified by Sanger and next-generation sequencing techniques, and predominant genomes were synthetically generated and cloned into T7-driven plasmids. Fully encapsidated DI particles (DIPs) were then generated using a rationally attenuated rCDV as a producer virus to drive DI genome replication. We demonstrate that these DIPs interfere with rCDV replication in a dose-dependent manner . Finally, we show sustained replication of a fluorescent DIP in experimentally infected ferrets over a period of 14 days. Most importantly, DIPs were isolated from the lymphoid tissues, which are a major site of CDV replication. Our established pipeline for detection, generation, and assaying DIPs is transferable to highly pathogenic paramyxoviruses and will allow qualitative and quantitative assessment of the therapeutic effects of DIP administration on disease outcome. Defective interfering (DI) genomes have long been considered inconvenient artifacts that suppressed viral replication . However, advances in sequencing technologies have led to DI genomes being identified in clinical samples, implicating them in disease progression and outcome. It has been suggested that DI genomes might be harnessed therapeutically. Negative-strand RNA virus research has provided a rich pool of natural DI genomes over many years, and they are probably the best understood . Here, we demonstrate the identification, synthesis, production, and experimental inoculation of novel CDV DI genomes in highly susceptible ferrets. These results provide important evidence that rationally designed and packaged DI genomes can survive the course of a wild-type virus infection.
缺陷干扰(DI)基因组限制病毒复制并诱导 I 型干扰素。由于 DI 基因组已被提议作为疫苗佐剂或治疗性抗病毒药物,因此了解其产生、描绘其作用机制、开发强大的生产能力、评估其安全性和持久性以及确定其长期影响非常重要。为了解决这个问题,我们从一个完全合成的分子克隆中生成了重组犬瘟热病毒(rCDV),该克隆使用了从一只患有犬瘟热的自由放养浣熊中获得的临床分离株的基因组序列进行设计。rCDV 被连续传代,以鉴定在 rCDV 复制过程中自然出现的 DI 基因组。通过 Sanger 和下一代测序技术鉴定缺陷基因组,并合成主要基因组并克隆到 T7 驱动的质粒中。然后使用合理减毒的 rCDV 作为生产病毒来生成完全包裹的 DI 颗粒(DIP)。我们证明这些 DIP 以剂量依赖的方式干扰 rCDV 复制。最后,我们展示了在实验感染的雪貂中,荧光 DIP 在 14 天的时间内持续复制。最重要的是,DIP 从淋巴组织中分离出来,这是 CDV 复制的主要部位。我们建立的 DIP 检测、生成和检测的流水线可转移到高致病性副粘病毒,并且可以对 DIP 给药对疾病结果的治疗效果进行定性和定量评估。缺陷干扰(DI)基因组长期以来一直被认为是抑制病毒复制的不便的人工制品。然而,测序技术的进步导致在临床样本中鉴定出 DI 基因组,这表明它们与疾病的进展和结果有关。有人提出,DI 基因组可能被用于治疗。多年来,负链 RNA 病毒研究为 DI 基因组提供了丰富的天然来源,并且它们可能是最被理解的。在这里,我们在高度易感的雪貂中证明了新型 CDV DI 基因组的鉴定、合成、生产和实验接种。这些结果提供了重要证据,表明经过合理设计和包装的 DI 基因组可以在野生型病毒感染过程中存活。